JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited
1.71
THB
-0.02
(-1.16%)
ISIN
THA520010R18
Return %
Stock
S&P 500
1Y
-0.58
14.20
3Y
-17.79
81.12
5Y
- -
68.34
Capital Structure
THB
•
in mil. unless spec.Working Capital
THB
•
in mil. unless spec.Growth Rates
THB
•
in mil. unless spec.Quarterly Revenue
THB
•
in mil. unless spec.Quarterly Earnings Per Share
THB
•
in mil. unless spec.Quarterly Dividends Per Share
THB
•
in mil. unless spec.Company Description
- CEO
- Pissanu Daengprasert
- Full Time Employees
- 270
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 255,257 Soi Sathupradit 58 Bangkok BM Thailand 10120
- IPO Date
- Nov 2, 2021
- Website
- jsppharma.com
- Similar Companies
- Business
- JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. (JSP.BK) develops, manufactures and distributes pharmaceuticals, dietary supplements, traditional medicines, herbal products, hemodialysis solutions and related medical supplies in Thailand. The company provides contract manufacturing services (OEM) for client brands as well as produces and sells own-brand products under trademarks including COX, Suphap Osot, EVITON and JSP; its dietary supplements encompass collagen peptides, multivitamins, 4 Mix Oil, Wolffia Cap, Acerola Cherry, coconut oil, fish oil, spirulina and beta-glucans; conventional medicines feature cough syrups and contraceptives; herbal and traditional medicines include Andrographis Paniculata pills, Curcuma Longa capsules, Compound Senna Laxative capsules, herbal cough lozenges and Reishi supplements, all produced under GMP/PIC/s standards; additional offerings comprise cosmetics, sanitizers, drug test kits and laboratory research, testing, training and consultancy services via subsidiaries. Operations span facilities in Bangkok and Lamphun province, targeting domestic markets with expansion into CLMV countries including Cambodia, Laos, Myanmar and Vietnam; founded in 2005 through the Daengprasert family's expansion from earlier pharmacy and COX Laboratories ventures dating to 1954, JSP is headquartered at 255/257 Soi Sathupradit 58, Yannawa, Bangkok. Recent developments include the 2023 establishment of subsidiaries JSP Pharma Holding Company Limited and full acquisition of CDIP (Thailand) Public Co., Ltd. for research services plus 52.8% stake in Grace Water Med Co., Ltd. for hemodialysis production; 2024 initiatives encompass relocation of dietary supplement production to Lamphun, expiration of JSP-W1 warrants yielding Baht 48.9 million, issuance of JSP-W2 warrants, capital adjustments and ongoing R&D in Wolffia extracts, hemp-derived herbs and chewable soft-gelatin capsules alongside expansion of conventional medicine lines to 20-25 million bottles annually.